The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies: STAMP and STRIDE.
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Janssen; Janssen; Lilly; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Harini Kandadi
Employment - Dendreon
Research Funding - Dendreon
 
Lawrence Fong
Consulting or Advisory Role - Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Raymond S. Lance
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Pfizer
 
Tuyen Vu
No Relationships to Disclose
 
Nadeem Anwar Sheikh
Employment - Dendreon
 
Neal D. Shore
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; Harpoon therapeutics; Kleo Pharmaceuticals; Tizona Therapeutics, Inc.
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Compugen; Janssen Oncology; Merck; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc.
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Merck Sharp & Dohme; Pfizer; Roche/Genentech